varisy的部落格

http://pdf.reuters.com/htmlnews/8knews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130222:nBw225193a

DUBLIN--(Business Wire)--

Research and Markets

(http://www.researchandmarkets.com/research/nsth6h/drg_insights) has announced
the addition of Decision Resources, Inc's new report "DRG Insights: Alzheimers
Disease" to their offering.

DRG Insights takes the most relevant information and insights from across our
portfolio for BioPharma and Med-Tech products and delivers the insight heavy
perspective that you need to generate better ideas and deliver more successful
campaigns and initiatives. Patients with osteoporosis and osteopenia are at
increased risk of suffering fractures.

These fractures place a considerable burden on public health systems, and
significant unmet need remains in the osteoporosis market for therapies that are
safer and more efficacious, particularly in reducing the risk of nonvertebral
fractures (e.g., hip fractures). The launch of several key new therapies,
coupled with changes in treatment guidelines and in physician prescribing
behavior, will lead to important market changes over the 2011-2021 forecast
period.

As the global population agesparticularly as the baby boomer generation begins
to turn 65the Alzheimer's disease (AD) population will grow rapidly. Despite the
large patient pool, however, only four compounds are approved for the treatment
of AD, all symptomatic ones with only modest efficacy of limited duration. Of
critical need are disease-modifying therapies (DMTs) that will slow the
progression of the disease (for patients early in the disease course) and
improved symptomatic therapies (for patients later in the disease course or for
those who may not be candidates for treatment with a DMT).

We forecast the launch of two potential DMTs in the next ten years, resulting in
a dramatic expansion of the AD market. The availability of improved diagnostics,
particularly amyloid imaging agents, will lead to earlier diagnosis and
facilitate increased uptake of expensive potential DMTs.

Key Topics Covered:

Executive Summary

Current Market Landscape

Etiology & Pathophysiology

Staging/Patient Segmentation

Select Drug Targets

Growth Drivers & Constraints

Key Metrics

Population Dynamics

Market Landscape

Current Therapies,

Treatment Algorithms

Country Specific Decision Trees

Comparison of Key Agents

Expert Insight on Prescribing Trends

Importance of Drug Attributes in Prescribing Decisions

Pricing & Reimbursement

Factors Influencing Pharmacy Director Tier Placement Decisions

Accessibility and Cost Hurdles

Reimbursement Environment

Unmet NeedsEmerging Therapies

Near-term Outlook

Long-term Outlook

Important Endpoints in Prescribing Decisions

Timelines

2010 and 2010 sales and Market Share

For more information visit
http://www.researchandmarkets.com/research/nsth6h/drg_insights

Source: Decision Resources, Inc

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Healthcare and Medical Devices, Pharmaceuticals

Copyright Business Wire 2013